mesenchymal stromal cells-derived exosomes with kras g12d sirna

Mesenchymal stromal cells-derived exosomes with KRAS G12D siRNA (often referred to as "iExosomes" or "iExoKras G12D") are engineered extracellular vesicles derived from human bone marrow mesenchymal stromal cells. These exosomes are loaded with small interfering RNA (siRNA) specifically targeting the oncogenic KRAS G12D mutation, a common driver in pancreatic ductal adenocarcinoma (PDAC). Upon administration, the exosome delivery system enables efficient and targeted transfer of the therapeutic siRNA into tumor cells harboring the KRAS G12D mutation, leading to silencing of mutant KRAS expression and downstream signaling pathways such as ERK phosphorylation. Preclinical studies have demonstrated favorable biodistribution to pancreatic tissue and minimal toxicity. In early-phase clinical trials, this therapy has shown safety and some evidence of disease stabilization in patients with advanced metastatic PDAC who have failed standard therapies. The approach leverages both direct inhibition of oncogenic signaling and potential immunomodulatory effects by increasing CD8+ T cell infiltration into tumors[1][2][3][5][7].

Brand names

iExoKrasG12DiExoKrasG-12DiExoKrasG 12D

Other names

Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNAMSC-derived Exosomes with KrasG12D siRNA